OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
APTNYSE$6.4864

ALPHA PRO TECH LTD

Medical Equipment & SuppliesRules + LLM

Alpha Pro Tech Ltd maintains a strong liquidity position with $16.88 million in cash and equivalents, and a current ratio of 19.81, indicating significant short-term financial flexibility. The company's price-to-book ratio of 1.06 and price-to-tangible-book ratio of 1.06 suggest that the market values the company's equity in line with its tangible book value. The debt-to-equity ratio of 0.0 indicates no leverage, which reduces financial risk but may also limit growth opportunities. The company's profitability metrics show a return on equity of 1.11% and a return on assets of 0.96%, which are below the industry median for medical equipment and supplies firms. This suggests that the company is not generating returns as efficiently as its peers. The gross profit of $5.52 million and operating income of $580,000 indicate that the company is profitable but faces challenges in converting revenue into net income. Alpha Pro Tech's revenue is concentrated in a few key segments, with a significant portion derived from construction and industrial products. The company's exposure to the construction sector is notable, as it relies on demand for housewrap and synthetic roof underlayment. The company also has a product line for protective apparel, including N-95 respirators, which experience increased demand during public health crises. The company's growth trajectory is influenced by its ability to bring new products to market and meet increased demand. Recent capital expenditures of $117,000 suggest ongoing investment in manufacturing capabilities. However, the company's free cash flow of -$105,000 indicates that it is currently spending more on operations than it is generating, which could impact its ability to fund future growth without external financing. The company faces medium dilution risk, as indicated by the risk assessment, with potential sources including future offerings to meet increased product demand. The company has also mentioned the possibility of stockpiling inventory during periods of high demand, which could lead to increased working capital requirements and potential markdowns if demand does not materialize. Recent events include the company's decision not to impair its investment in Harmony as of March 31, 2026, and December 31, 2025. The company is also expanding its manufacturing capacity in Valdosta, Georgia, and through its joint venture in India to support new product offerings. These developments suggest a strategic focus on scaling production to meet anticipated demand for its products.

30-day price · APT+0.96 (+21.3%)
Low$4.50High$7.50Close$5.47As of8 Jun, 00:00 UTC
Profile
CompanyALPHA PRO TECH LTD
ExchangeNYSE
TickerAPT
CIK0000884269
SICOrthopedic, Prosthetic & Surgical Appliances & Supplies
SectorHealthcare
BusinessHealthcare Equipment & Supplies
Industry groupMedical Equipment, Supplies & Distribution
IndustryMedical Equipment & Supplies
AI analysis

Business. Alpha Pro Tech Ltd designs, develops, and markets performance-based products for the construction, industrial, and protective apparel markets, including housewrap, synthetic roof underlayment, and N-95 respirators.

Classification. The company is classified in the Healthcare sector under Medical Equipment & Supplies with 0.70 confidence based on rule-based classification.

Alpha Pro Tech Ltd maintains a strong liquidity position with $16.88 million in cash and equivalents, and a current ratio of 19.81, indicating significant short-term financial flexibility. The company's price-to-book ratio of 1.06 and price-to-tangible-book ratio of 1.06 suggest that the market values the company's equity in line with its tangible book value. The debt-to-equity ratio of 0.0 indicates no leverage, which reduces financial risk but may also limit growth opportunities. The company's profitability metrics show a return on equity of 1.11% and a return on assets of 0.96%, which are below the industry median for medical equipment and supplies firms. This suggests that the company is not generating returns as efficiently as its peers. The gross profit of $5.52 million and operating income of $580,000 indicate that the company is profitable but faces challenges in converting revenue into net income. Alpha Pro Tech's revenue is concentrated in a few key segments, with a significant portion derived from construction and industrial products. The company's exposure to the construction sector is notable, as it relies on demand for housewrap and synthetic roof underlayment. The company also has a product line for protective apparel, including N-95 respirators, which experience increased demand during public health crises. The company's growth trajectory is influenced by its ability to bring new products to market and meet increased demand. Recent capital expenditures of $117,000 suggest ongoing investment in manufacturing capabilities. However, the company's free cash flow of -$105,000 indicates that it is currently spending more on operations than it is generating, which could impact its ability to fund future growth without external financing. The company faces medium dilution risk, as indicated by the risk assessment, with potential sources including future offerings to meet increased product demand. The company has also mentioned the possibility of stockpiling inventory during periods of high demand, which could lead to increased working capital requirements and potential markdowns if demand does not materialize. Recent events include the company's decision not to impair its investment in Harmony as of March 31, 2026, and December 31, 2025. The company is also expanding its manufacturing capacity in Valdosta, Georgia, and through its joint venture in India to support new product offerings. These developments suggest a strategic focus on scaling production to meet anticipated demand for its products.
Key takeaways
  • Alpha Pro Tech Ltd has a strong liquidity position with a current ratio of 19.81 and $16.88 million in cash and equivalents.
  • The company's profitability metrics, including a return on equity of 1.11%, are below the industry median, indicating inefficiencies in converting revenue into net income.
  • Revenue is concentrated in construction and industrial products, with a notable reliance on demand for housewrap and synthetic roof underlayment.
  • The company is investing in manufacturing capabilities to meet increased product demand, but its free cash flow of -$105,000 suggests current operational spending exceeds cash generation.
  • Medium dilution risk is present, with potential sources including future offerings to support growth initiatives.
  • Recent strategic moves include expanding manufacturing in Valdosta, Georgia, and through a joint venture in India to support new product offerings.
  • --
  • # RATIONALES
Financial snapshot
PeriodQ1 2026
CurrencyUSD
Revenue
Gross profit$5.5M
Operating income$580.0k
Net income$702.0k
R&D
SG&A
D&A$250.0k
SBC$132.0k
Operating cash flow$12.0k
CapEx$117.0k
Free cash flow-$105.0k
Total assets$73.0M
Total liabilities$10.0M
Total equity$63.0M
Cash & equivalents$16.9M
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$3.8M$3.5M$1.7M
FY2024$3.4M$3.9M$1.9M
FY2025$3.4M$3.9M$1.9M
FY2023$4.1M$4.2M$7.7M
FY2024$4.1M$4.2M$7.7M
PeriodGross %Op %Net %FCF %
FY2025
FY2024
FY2025
FY2023
FY2024
PeriodAssetsEquityCashDebt
FY2025$74.1M$62.5M$17.0M
FY2024$73.7M$62.2M$18.6M
FY2025$73.7M$62.2M$18.6M
FY2023$68.8M$61.6M$20.4M
FY2024$68.8M$61.6M$20.4M
PeriodOCFCapExFCFSBC
FY2025$2.4M$639.0k$1.7M$540.0k
FY2024$5.7M$3.8M$1.9M$463.0k
FY2025$5.7M$3.8M$1.9M$463.0k
FY2023$8.5M$792.0k$7.7M$170.0k
FY2024$8.5M$792.0k$7.7M$170.0k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q1 2026$580.0k$702.0k-$105.0k
Q1 2026
Q3 2025$2.9M$2.8M$1.7M
Q2 2025$1.8M$1.9M-$2.1M
PeriodGross %Op %Net %FCF %
Q1 2026
Q1 2026
Q3 2025
Q2 2025
PeriodAssetsEquityCashDebt
Q1 2026$73.0M$63.0M$16.9M
Q1 2026$74.1M$62.5M$17.0M
Q3 2025$73.9M$62.5M$17.7M
Q2 2025$73.2M$62.2M$14.5M
PeriodOCFCapExFCFSBC
Q1 2026$12.0k$117.0k-$105.0k$132.0k
Q1 2026
Q3 2025$2.1M$372.0k$1.7M$408.0k
Q2 2025-$1.9M$273.0k-$2.1M$272.0k
Valuation
Market price$6.48
Market cap$66.9M
Enterprise value$50.1M
P/E95.4
Reported non-GAAP P/E
EV/Revenue
EV/Op income86.3
EV/OCF4172.2
P/B1.1
P/Tangible book1.1
Tangible book$63.0M
Net cash$16.9M
Current ratio19.8
Debt/Equity0.0
ROA1.0%
ROE1.1%
Cash conversion2.0%
CapEx/Revenue
SBC/Revenue
Asset intensity0.1
Dilution ratio2.0%
Risk assessment
Dilution riskMedium
Liquidity riskLow
  • Source documents mention dilution or offering risk.
Industry benchmarks
Activity: Medical Devices · cohort 3 companies
MetricAPTActivity
Op margin-53.7% medp25 -69.8% · p75 -42.5%
Net margin-50.1% medp25 -54.5% · p75 -40.0%
Gross margin68.2% medp25 28.3% · p75 73.0%
R&D / revenue16.0% medp25 9.2% · p75 19.3%
CapEx / revenue3.2% medp25 1.7% · p75 9.8%
Debt / equity0.0%6.1% medp25 3.5% · p75 8.7%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 01:28 UTC#df749f83
Market quoteclose USD 6.48 · shares 0.01B diluted
no public URL
2026-05-12 01:28 UTC#b1249fe1
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 09:16 UTCJob: 7680bb11